Literature DB >> 8494388

In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci.

T Lawrence1, C Rotstein, T R Beam, E A Gorzynski, D Amsterdam.   

Abstract

The susceptibilities of 316 gram-positive bacteremic isolates to ramoplanin, vancomycin, and teicoplanin and seven other antibiotics were tested. Ramoplanin demonstrated MICs of < or = 0.25 microgram/ml for at least 99% of Staphylococcus aureus isolates and 100% of coagulase-negative staphylococci tested. For both oxacillin-susceptible and oxacillin-resistant S. aureus and coagulase-negative staphylococci, the activity of ramoplanin surpassed those of both vancomycin and teicoplanin. Ramoplanin and teicoplanin had comparable activities against enterococci and Streptococcus pneumoniae and were superior to vancomycin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8494388      PMCID: PMC187804          DOI: 10.1128/AAC.37.4.896

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

Review 1.  Vancomycin- and erythromycin-induced hearing loss in humans.

Authors:  R E Brummett; K E Fox
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

2.  Antimicrobial susceptibility of vancomycin-resistant Leuconostoc, Pediococcus, and Lactobacillus species.

Authors:  J M Swenson; R R Facklam; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

3.  In vitro evaluation of ramoplanin (MDL 62198, A 16686)

Authors:  S Dixson; W Brumfitt; J M Hamilton-Miller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267

4.  In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.

Authors:  A Bartoloni; M G Colao; A Orsi; R Dei; E Giganti; F Parenti
Journal:  J Antimicrob Chemother       Date:  1990-11       Impact factor: 5.790

5.  In vitro evaluation of ramoplanin (A16686 or MDL62198). A new depsipeptide complex for potential topical use.

Authors:  R N Jones; A L Barry
Journal:  Diagn Microbiol Infect Dis       Date:  1989 May-Jun       Impact factor: 2.803

6.  Mild nephrotoxicity associated with vancomycin use.

Authors:  N J Downs; R E Neihart; J M Dolezal; G R Hodges
Journal:  Arch Intern Med       Date:  1989-08

7.  Bactericidal activity of ramoplanin against antibiotic-resistant enterococci.

Authors:  C C Johnson; S Taylor; P Pitsakis; P May; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

8.  Vancomycin toxicity: a prospective study.

Authors:  J A Mellor; J Kingdom; M Cafferkey; C T Keane
Journal:  J Antimicrob Chemother       Date:  1985-06       Impact factor: 5.790

9.  Comparative in-vitro activity of vancomycin, teicoplanin, ramoplanin (formerly A16686), paldimycin, DuP 721 and DuP 105 against methicillin and gentamicin resistant Staphylococcus aureus.

Authors:  P A Maple; J M Hamilton-Miller; W Brumfitt
Journal:  J Antimicrob Chemother       Date:  1989-04       Impact factor: 5.790

10.  The in vitro activity of ramoplanin (A-16686/MDL 62,198), vancomycin and teicoplanin against methicillin-susceptible and methicillin-resistant Staphylococcus spp.

Authors:  M D O'Hare; D Felmingham; R N Grüneberg
Journal:  Drugs Exp Clin Res       Date:  1988
View more
  6 in total

Review 1.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

2.  Activity of teicoplanin and vancomycin against penicillin-resistant pneumococci.

Authors:  K P Klugman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-01       Impact factor: 3.267

3.  Comparison of agar dilution, tube dilution, and broth microdilution susceptibility tests for determination of ramoplanin MICs.

Authors:  M T Kenny; M A Brackman
Journal:  J Clin Microbiol       Date:  1994-05       Impact factor: 5.948

Review 4.  In vitro activity of fluoroquinolones against gram-positive bacteria.

Authors:  G M Eliopoulos
Journal:  Drugs       Date:  1995       Impact factor: 9.546

5.  In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.

Authors:  D M Citron; C V Merriam; K L Tyrrell; Y A Warren; H Fernandez; E J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

6.  Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis.

Authors:  M de Górgolas; P Avilés; C Verdejo; M L Fernández Guerrero
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.